Generated by AI
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to support scalable manufacturing of engineered and native iNKT cell programs, with a pipeline that includes therapies for solid tumors and inflammatory conditions. MiNK Therapeutics works at the intersection of cell therapy and immunology, using iNKT cells that are intended to combine tumor-targeting activity with immune-regulating properties. Its current work centers on advancing product candidates through clinical development and building a manufacturing approach suited to reproducible, off-the-shelf delivery. Headquartered in New York, MiNK Therapeutics plays a specialized role in the biotechnology market by developing precision immunotherapies for serious diseases with limited treatment options.
Website149 Fifth Avenue
New York, NY, 10010
United States
The latest articles about INKT.
Summary of May 28's posts. Generated by AI.
Summary of Mar 27's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Mar 27's posts. Generated by AI.
Investors talking about INKT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.